Enhanced GS® CHO Vector Technology For Improved Expression Control Of Biotherapeutic Proteins

Traditional expression platforms, often optimized for monoclonal antibodies, have limitations when applied to emerging biotherapeutic formats like multichain asymmetric antibodies and bispecifics. In this webinar, Dr. Peter O'Callaghan from Lonza discusses the evolution of GS® vector technology. This advanced platform aims to enhance expression control, boost yields, and improve stability in CHOK1SV GS-KO® cells, making it suitable for a wider range of complex biotherapeutics.

Key Takeaways:

• Understanding the Limitations: Explore the challenges associated with current expression systems, especially in the context of intricate biotherapeutic formats.
• Advancing Vector Technology: Learn about the innovations in GS® vector technology designed to optimize expression, increase production yields, and ensure consistent protein quality.
• Overcoming Expression Challenges: Discover how Lonza's cutting-edge solutions address the unique demands of diverse biotherapeutic formats.

Gain insights into the latest advancements in protein expression and their potential to revolutionize the development of next-generation biotherapeutics.